HC Wainwright Predicts AC Immune’s Q1 Earnings (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of AC Immune in a research report issued on Monday, March 16th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune’s Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.22) EPS.

A number of other research firms also recently weighed in on ACIU. Jefferies Financial Group reaffirmed a “buy” rating and set a $7.00 price target on shares of AC Immune in a research note on Friday. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research note on Monday. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

AC Immune Price Performance

Shares of NASDAQ ACIU opened at $3.13 on Tuesday. The business’s 50-day moving average price is $3.14 and its two-hundred day moving average price is $3.04. AC Immune has a one year low of $1.43 and a one year high of $4.00. The company has a market capitalization of $314.28 million, a P/E ratio of -3.73 and a beta of 1.64.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Friday, March 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. AC Immune had a negative net margin of 1,977.71% and a negative return on equity of 92.65%. The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $1.14 million.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC lifted its holdings in shares of AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of AC Immune by 20.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock worth $670,000 after acquiring an additional 36,353 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of AC Immune in the third quarter worth $549,000. Marshall Wace LLP bought a new position in AC Immune during the fourth quarter worth $586,000. Finally, Sei Investments Co. bought a new position in AC Immune during the second quarter worth $51,000. 51.36% of the stock is owned by institutional investors.

AC Immune Company Profile

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.